Table 3.

Pharmacological targets for the modulation of dopaminergic and adrenergic pathways by agents targeting storage and release (brand/street names in parentheses).

Reuptake inhibitors/transporter blockers
DAT inhibitors	Methylphenidate (Ritalin, Focalin, Concerta), bupropion (Wellbutrin, Zyban), amineptine (Survector, Maneon, Directin), nomifensine (Merital, Alival), cocaine, methylenedioxypyrovalerone (MDPV; “Sonic”), ketamine (K; Ketalar, Ketanest, Ketaset; “Special-K”, “Kit Kat”, etc.), phencyclidine (PCP; Sernyl; “Angel Dust”, “Rocket Fuel”, etc.)
Indications	Attention-deficit hyperactivity disorder (ADHD), narcolepsy, obesity as anorectics, depression and anxiety, drug addiction, sexual dysfunction, illicit street drugs
VMAT2 inhibitors	Reserpine (Serpasil), tetrabenazine (Nitoman, Xenazine), deserpidine (Harmonyl)
Indications	Sympatholytics or antihypertensives, antipsychotics
Releasing agents	Amphetamine (Adderall, Dexedrine; “Speed”), lisdexamfetamine (Vyvanse), methamphetamine (Desoxyn; “Meth”, “Crank”, “Crystal”, etc.), methylenedioxymethamphetamine (MDMA; “Ecstasy”, “E”, “X”, “XTC”, etc.), phenmetrazine (Preludin; “Prellies”), pemoline (Cylert), 4-methylaminorex (4-MAR; “Ice”, “Euphoria”, etc.), benzylpiperazine (BZP; “Bennies”, “A2”, “Sunrise”, “Frenzy”, etc.)
Indications	Attention-deficit hyperactivity disorder (ADHD), narcolepsy, obesity, depression and anxiety, drug addiction, sexual dysfunction, illicit street drugs
“Activity enhancers”	Benzofuranylpropylaminopentane (BPAP), phenylpropylaminopentane (PPAP)
Indications	Investigational: Alzheimer’s disease, Parkinson’s disease and clinical depression

DAT, dopamine transporter; VMAT2, vesicular monoamine transporter type 2.